659 Shares in IDEXX Laboratories, Inc. $IDXX Bought by Paloma Partners Management Co

Key Points

• Paloma Partners Management Co purchased 659 shares of IDEXX Laboratories, Inc. valued at approximately $277,000, as reported in their latest SEC filing.
• IDEXX Laboratories had a strong earnings report, with $3.63 EPS exceeding estimates and a 10.6% year-over-year revenue increase to $1.11 billion.
• Insider transactions included CEO Jonathan Jay Mazelsky selling 29,260 shares for over $18 million, indicating a significant decrease in his ownership stake.

Paloma Partners Management Co purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 659 shares of the company's stock, valued at approximately $277,000.

Several other large investors also recently bought and sold shares of IDXX. MorganRosel Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 1st quarter valued at about $26,000. Colonial Trust Co SC grew its stake in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares during the period. WPG Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $37,000. Finally, Bank of Jackson Hole Trust lifted its holdings in shares of IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Activity

In related news, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This trade represents a 46.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Lane sold 8,411 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the sale, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock worth $34,293,468 over the last three months. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Up 1.0%

Shares of IDXX traded up $6.49 during midday trading on Thursday, reaching $640.44. The stock had a trading volume of 440,527 shares, compared to its average volume of 706,554. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The company's fifty day simple moving average is $588.74 and its two-hundred day simple moving average is $504.04. The company has a market cap of $51.24 billion, a price-to-earnings ratio of 53.33, a PEG ratio of 4.19 and a beta of 1.56. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the business earned $2.44 EPS. The company's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on IDXX shares. JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a report on Monday, August 4th. BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price on the stock. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a report on Monday, August 4th. Finally, Morgan Stanley increased their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.